Bioniq, founded in 2019 and known for its personalized nutritional supplements based on blood biomarker data, has announced that football star Diogo Dalot, right-back for Manchester United and the Portugal national team, is on-board with the company as an investor, contributing over €1 million.
Dalot joins global football icon Cristiano Ronaldo, who became a major investor in Bioniq in 2024, and helped to take Bioniq’s total valuation to US$82 million.
Dalot’s investment is seen to mark another milestone in Bioniq’s mission to build its brand and the reach of its personalized nutrition for athletes and the general public worldwide.
“When it comes to high-level performance, my biggest focus has always been finding that extra 1% – the key to setting myself apart from the rest,” said Diogo Dalot.
“Since discovering Bioniq in 2022, it’s been a game-changer for me. I’ve seen the results for myself. Achieving such progress is only possible with a product that’s truly personalized and tailored specifically to my needs.
“Now, I’m thrilled to take the next step as an investor. I believe in Bioniq’s mission and see the tremendous potential of this business, especially with the growing global demand for personalized nutrition.”
In addition to integrating the Bioniq formula into his daily routine, Dalot’s commitment extends to an active collaboration with the Bioniq team on product innovation, contributing his insights as a professional athlete. With the launch of Bioniq’s personalized supplement, Build Your Own, Dalot has created a more precise supplement routine, allowing him to vary his nutrient intake based on his performance goals.
“Diogo has an exceptional approach to performance optimization and recovery, constantly seeking the most effective and scientifically backed methods to enhance his physical and cognitive capabilities,” said Vadim Fedotov, Founder and CEO of Bioniq.
“His dedication to craft and commitment to maximizing potential makes him a perfect fit for Bioniq. He shares our vision and mission, recognizing that the future of health lies in precision, personalization, and efficacy. His investment is yet another testament to this shift — where science-driven, individualized solutions create meaningful impact in the industry and everyday well-being.”
Bioniq was developed by scientists to improve the physical and cognitive function of Olympic athletes. Today, products are available for customers across 70 countries, with its total user base reportedly growing more than 10x in 2024. Bioniq adds that it is projected to grow at a CAGR (compound annual growth rate) of 9.1% from 2024 to 2030.
Dalot’s investment follows the 2024 investment by Cristiano Ronaldo, as well as a successful Series B round, which raised US$15 million, led by Principal Investors HV Capital and Unbound, two leading European venture capital firms.
